Literature DB >> 23254962

Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.

Si Wei Li1, Hua Wang, Mei Lian Liu, Hai Bo Zhang, Yan Qun Xiang, Xing Lv, Wei Xiong Xia, Mu Sheng Zeng, Hai Qiang Mai, Ming Huang Hong, Xiang Guo.   

Abstract

The purpose of this prospective study is to investigate the predictive and prognostic significance of the Raf kinase inhibitory protein (RKIP) in locoregionally advanced nasopharyngeal carcinoma (NPC). Immunohistochemical assays were performed to detect the RKIP protein expression of samples from 212 patients with locoregionally advanced NPC. All patients were assigned randomly into the inductive chemotherapy plus radiation therapy (IC + RT) group, the concurrent chemoradiotherapy (CCRT) group, the inductive chemotherapy plus concurrent chemoradiotherapy (IC + CCRT) group, and the radiation therapy alone (RT) group. The patients in the IC + RT group were treated with IC using 2-3 cycles of cisplatin (80 mg/m(2)) and fluorouracil (500 mg/m(2)), repeated every 3 weeks, followed by radiotherapy. Those in the CCRT group were treated with weekly cisplatin (40 mg/m(2)) for 6-7 cycles during radiotherapy. In the IC + CCRT group, the chemotherapy prior to radiation was similar to the cisplatin-fluorouracil regimen in the IC + RT group, whereas it cisplatin regimen was identical to that in the CCRT group. The results show that RKIP is an independent prognostic factor for 5-year distant metastasis-free survival (DMFS), overall survival (OS), and progression-free survival (PFS). Patients with high RKIP expression benefited more from reduced metastasis in the IC + RT and the IC + CCRT group, with improved OS and PFS in each treatment group compared with that among patients with low RKIP expression. In the high RKIP expression subgroup, chemotherapy combined with radiotherapy improved the DMFS when compared with the RT group, but this effect was not observed in the low RKIP expression subgroup. RKIP was predictive of distant metastasis with good sensitivity and specificity. Clinically, high RKIP expression inhibited distant metastasis in advanced NPC, and its detection might be used to predict distant metastasis with good sensitivity and specificity. The effect of chemotherapy on distant metastasis in combined chemoradiotherapy might be related to the RKIP expression level. Patients with high RKIP expression showed more improved OS and PFS than their low RKIP expression counterparts. Higher RKIP expression improves the DMFS of patients who receive inductive high-dose cisplatin-based chemoradiotherapy, with or without concurrent cisplatin. Low RKIP expression is also a predictive marker for cancer progression and metastasis, which could be used to stratify patients with high risk of metastasis and death.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23254962     DOI: 10.1007/s12032-012-0322-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  31 in total

1.  [Expression clinical significance of nm23-H1 and vessel endothelium growth factor protein in nasopharyngeal carcinoma].

Authors:  Wu-zhong Jiang; Yu-ping Liao; Su-ping Zhao; Hai-jun Wu
Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2006-03

Review 2.  Viral infection and cancer: the NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes.

Authors:  Stavroula Baritaki; Benjamin Bonavida
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

3.  MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells.

Authors:  Gang Li; Zhengrong Wu; Ying Peng; Xiong Liu; Juan Lu; Lu Wang; Qiuhui Pan; Min-Liang He; Xiang-Ping Li
Journal:  Cancer Lett       Date:  2010-08-21       Impact factor: 8.679

4.  Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.

Authors:  Lei Chen; Chao-Su Hu; Xiao-Zhong Chen; Guo-Qing Hu; Zhi-Bin Cheng; Yan Sun; Wei-Xiong Li; Yuan-Yuan Chen; Fang-Yun Xie; Shao-Bo Liang; Yong Chen; Ting-Ting Xu; Bin Li; Guo-Xian Long; Si-Yang Wang; Bao-Min Zheng; Ying Guo; Ying Sun; Yan-Ping Mao; Ling-Long Tang; Yu-Ming Chen; Meng-Zhong Liu; Jun Ma
Journal:  Lancet Oncol       Date:  2011-12-07       Impact factor: 41.316

5.  Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.

Authors:  Giuseppe Pasqualetti; Simona Ricciardi; Valentina Mey; Mario Del Tacca; Romano Danesi
Journal:  Lung Cancer       Date:  2011-05-06       Impact factor: 5.705

6.  Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.

Authors:  Hong Zhao Li; Yue Wang; Yan Gao; Jie Shao; Xiu Lan Zhao; Wei Min Deng; Yi Xin Liu; Jie Yang; Zhi Yao
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

7.  Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.

Authors:  Stavroula Baritaki; Kam Yeung; Michael Palladino; James Berenson; Benjamin Bonavida
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

8.  Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis.

Authors:  Zheng Fu; Peter C Smith; Lizhi Zhang; Mark A Rubin; Rodney L Dunn; Zhi Yao; Evan T Keller
Journal:  J Natl Cancer Inst       Date:  2003-06-18       Impact factor: 13.506

9.  Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.

Authors:  Lu Han; Shao-Jun Lin; Jian-Ji Pan; Chuan-Ben Chen; Yu Zhang; Xiu-Chun Zhang; Xi-Yi Liao; Qi-Song Chen
Journal:  Chin J Cancer       Date:  2010-02

10.  A new model for raf kinase inhibitory protein induced chemotherapeutic resistance.

Authors:  Fahd Al-Mulla; Milad S Bitar; Jingwei Feng; Sungdae Park; Kam C Yeung
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

View more
  5 in total

Review 1.  A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics.

Authors:  Yuhao Wang; Benjamin Bonavida
Journal:  Crit Rev Oncog       Date:  2018

2.  RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway.

Authors:  Hongyi Liu; Peng Li; Bing Li; Peng Sun; Jiajin Zhang; Baishi Wang; Baoqing Jia
Journal:  Tumour Biol       Date:  2014-12-30

3.  Expression of RKIP in chronic myelogenous leukemia K562 cell and inhibits cell proliferation by regulating the ERK/MAPK pathway.

Authors:  Bin Li; Baolan Sun; Jianwei Zhu; Nina Zhou; Zhiping Yang; Jianhui Gu
Journal:  Tumour Biol       Date:  2014-10

4.  Multifunctional gold nanostar conjugates for tumor imaging and combined photothermal and chemo-therapy.

Authors:  Haiyan Chen; Xin Zhang; Shuhang Dai; Yuxiang Ma; Sisi Cui; Samuel Achilefu; Yueqing Gu
Journal:  Theranostics       Date:  2013-08-03       Impact factor: 11.556

Review 5.  The biological complexity of RKIP signaling in human cancers.

Authors:  Ammad Ahmad Farooqi; Yiwei Li; Fazlul H Sarkar
Journal:  Exp Mol Med       Date:  2015-09-25       Impact factor: 8.718

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.